Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM).MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.Novel therapeutics are needed for PCL, and daratumumab may play role.We report a case of relapsed/refractory multiple myeloma (RRM